Keyword: PsiOxus Therapeutics
The week’s biotech developments included a brain-penetrating compound from scorpion venom and a pact to develop virus-based cancer drugs.
PsiOxus Therapeutics has a green light for trials of its cancer-killing virus therapy for solid tumors, sparking a $15 million milestone payment.
PsiOxus thinks it has figured out how to systemically deliver viruses that only replicate in tumor cells. That turned heads at Bristol-Myers Squibb, which struck two deals with PsiOxus last year and provided a launchpad for a pipeline that uses viruses to directly kill cancer cells.
The philosophy of Fierce 15 is a simple one: We want to see the best science combined with the brightest teams, and we want to see the promise that they hold in their hands has a genuine chance of being the Next Big Thing. Here are this year's standouts.
Bristol-Myers Squibb has signed a new preclinical deal with British biotech PsiOxus to work on its oncolytic virus NG-348 in a deal that could be worth just shy of $1 billion.
Bristol-Myers Squibb and PsiOxus Therapeutics have partnered to put a pair of candidates into Phase I testing to treat several tumor types in late-stage cancer patients.